Germany-based Bayer HealthCare and US-based Onyx Pharmaceuticals have announced that the US Food and Drug Administration (FDA) has approved Nexavar (sorafenib), an oral multi-kinase inhibitor, for the treatment of patients with ...
Bayer HealthCare and Onyx Pharmaceuticals have announced FDA priority review designation for Nexavar (sorafenib) supplemental new drug application for the treatment of radioactive iodine-refractory differentiated thyroid cancer. Nexavar ...
Tags: New Drug Application, FDA
Biotechnology company Amgen has reached a deal to buy all outstanding shares of California-based Onyx Pharmaceuticals for $125 per share in cash. The purchase price of the transaction that is expected to be closed by the beginning of ...
Tags: Amgen, Onyx Pharmaceuticals
Onyx Pharmaceuticals, a licensee of Ligand Pharmaceuticals, has gained FDA approval for Kyprolis (carfilzomib) for injection. Kyprolis is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have ...
Tags: Onyx Pharmaceuticals, Ligand Pharmaceuticals, Kyprolis
The US FDA has granted priority review designation to Bayer HealthCare's new drug application (NDA) filed for regorafenib to treat patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard ...
Tags: US FDA, Bayer HealthCare, NDA